REGN · Regeneron Pharmaceuticals Inc. Common Stock
View on chartInsiders & Stakes
| George Yancopoulos President and Chief Scientific | ▼ Sell | Tax Withholding | 310,460 Shares held | 12/31/2025 | View profile |
| Leonard S. Schleifer President & CEO | ▼ Sell | Tax Withholding | 214,523 Shares held | 12/31/2025 | View profile |
| VAGELOS P ROY Director | ▼ Sell | Gift | 125,493 Shares held | 4/3/2023 | View profile |
| STAHL NEIL EVP Research and Development | ▼ Sell | Tax Withholding | 48,829 Shares held | 12/16/2024 | View profile |
| Andrew J. Murphy EVP Research | ▼ Sell | Tax Withholding | 47,833 Shares held | 12/9/2025 | View profile |
| Joseph J. Larosa EVP General Counsel and Secret | ▼ Sell | Tax Withholding | 36,373 Shares held | 8/19/2026 | View profile |
| George L. Sing Director | ▲ Buy | Grant | 31,007 Shares held | 1/2/2026 | View profile |
| Robert E. Landry EVP Finance CFO | ▼ Sell | Tax Withholding | 23,693 Shares held | 2/2/2024 | View profile |
| Van Plew Daniel P EVP & General Mgr, Industrial | ▼ Sell | Tax Withholding | 21,673 Shares held | 12/9/2025 | View profile |
| Christopher R. Fenimore SVP Controller | ▼ Sell | Tax Withholding | 19,984 Shares held | 8/18/2026 | View profile |
| Arthur F. Ryan Director | ▼ Sell | Open Market | 17,303 Shares held | 7/2/2026 | View profile |
| Marion McCourt EVP Commercial | ▼ Sell | Open Market | 12,003 Shares held | 9/3/2026 | View profile |
| Joseph L. Goldstein Director | ▲ Buy | Grant | 6,703 Shares held | 1/2/2026 | View profile |
| Christine A. Poon Director | ▲ Buy | Grant | 5,219 Shares held | 1/2/2026 | View profile |
| Jason Pitofsky VP Controller | ▼ Sell | Open Market | 4,272 Shares held | 2/9/2026 | View profile |
| Tessier-Lavigne Marc Director | ▲ Buy | Grant | 2,434 Shares held | 1/3/2023 | View profile |
| N. Anthony Coles Director | ▲ Buy | Grant | 1,714 Shares held | 1/2/2026 | View profile |
| Huda Y. Zoghbi Director | ▼ Sell | Open Market | 1,703 Shares held | 8/10/2026 | View profile |
| Bonnie L. Bassler Director | ▼ Sell | Open Market | 1,703 Shares held | 1/7/2026 | View profile |
| Michael S. Brown Director | ▲ Buy | Grant | 1,703 Shares held | 1/2/2026 | View profile |
| Craig B. Thompson Director | ▲ Buy | Grant | 775 Shares held | 1/2/2026 | View profile |
| Kathryn Guarini Director | ▼ Sell | Open Market | 603 Shares held | 9/2/2026 | View profile |
| David P. Schenkein Director | ▲ Buy | Grant | 603 Shares held | 1/2/2026 | View profile |
Transaction History
| Marion McCourt | ▼ Sell | Open Market | 1,131 | $970K | 9/3/2026 |
| Marion McCourt | ▼ Sell | Open Market | 1,215 | $1.0M | 9/2/2026 |
| Kathryn Guarini | ▲ Buy | Option Exercise | 400 | $288K | 9/2/2026 |
| Kathryn Guarini | ▼ Sell | Open Market | 400 | $340K | 9/2/2026 |
| Joseph J. Larosa | ▲ Buy | Option Exercise | 12,282 | $4.7M | 8/19/2026 |
| Joseph J. Larosa | ▼ Sell | Tax Withholding | 9,019 | $7.5M | 8/19/2026 |
| Christopher R. Fenimore | ▲ Buy | Option Exercise | 6,283 | $2.4M | 8/18/2026 |
| Christopher R. Fenimore | ▼ Sell | Tax Withholding | 4,599 | $3.7M | 8/18/2026 |
| Kathryn Guarini | ▲ Buy | Option Exercise | 400 | $288K | 8/10/2026 |
| Kathryn Guarini | ▼ Sell | Open Market | 400 | $320K | 8/10/2026 |
| Huda Y. Zoghbi | ▲ Buy | Option Exercise | 800 | $301K | 8/10/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 800 | $640K | 8/10/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 200 | $130K | 7/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $4K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 15 | $11K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 24 | $17K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 15 | $11K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 14 | $10K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 7 | $5K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 4 | $3K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 6 | $4K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $1K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $4K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $712 | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $1K | 5/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 14 | $11K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 13 | $10K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 9 | $7K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 40 | $31K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $771 | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 8 | $6K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 8 | $6K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 3 | $2K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 4 | $3K | 4/1/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 7 | $5K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $4K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 3 | $2K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 10 | $8K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 9 | $7K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 11 | $9K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 7 | $6K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 20 | $16K | 3/2/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 20 | $16K | 3/2/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 209 | $163K | 2/19/2026 |
| Huda Y. Zoghbi | ▲ Buy | Option Exercise | 1,638 | $617K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 298 | $233K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 56 | $44K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 49 | $38K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 50 | $39K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 53 | $41K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 208 | $162K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 331 | $258K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 160 | $126K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 220 | $172K | 2/19/2026 |
| Huda Y. Zoghbi | ▼ Sell | Open Market | 4 | $3K | 2/19/2026 |
| Jason Pitofsky | ▲ Buy | Option Exercise | 1,000 | $492K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 20 | $16K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 521 | $405K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 563 | $438K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 205 | $160K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 75 | $59K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 26 | $20K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 37 | $29K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 3 | $2K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $785 | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $786 | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 144 | $113K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 1 | $785 | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 53 | $42K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $776 | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 10 | $8K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 57 | $44K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 12 | $9K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $4K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $780 | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $4K | 2/9/2026 |
| Jason Pitofsky | ▼ Sell | Open Market | 391 | $304K | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $783 | 2/9/2026 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $788 | 2/9/2026 |
| Bonnie L. Bassler | ▲ Buy | Option Exercise | 1,500 | $561K | 1/7/2026 |
| Bonnie L. Bassler | ▼ Sell | Open Market | 1,500 | $1.2M | 1/7/2026 |
| Kathryn Guarini | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Joseph L. Goldstein | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Arthur F. Ryan | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| N. Anthony Coles | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Bonnie L. Bassler | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| George L. Sing | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Christine A. Poon | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Michael S. Brown | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Craig B. Thompson | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| Huda Y. Zoghbi | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| David P. Schenkein | ▲ Buy | Grant | 155 | $0 | 1/2/2026 |
| George Yancopoulos | ▼ Sell | Tax Withholding | 28,570 | $22.1M | 12/31/2025 |
| Leonard S. Schleifer | ▲ Buy | Option Exercise | 28,570 | $0 | 12/31/2025 |
| Leonard S. Schleifer | ▼ Sell | Tax Withholding | 28,570 | $22.1M | 12/31/2025 |
| George Yancopoulos | ▲ Buy | Option Exercise | 28,570 | $0 | 12/31/2025 |
| George L. Sing | ▲ Buy | Option Exercise | 9,212 | $4.8M | 12/30/2025 |
| George L. Sing | ▼ Sell | Tax Withholding | 6,188 | $4.8M | 12/30/2025 |
| Leonard S. Schleifer | ▼ Sell | Tax Withholding | 155,145 | $108.8M | 12/9/2025 |
| Leonard S. Schleifer | ▲ Buy | Option Exercise | 172,723 | $96.0M | 12/9/2025 |
| Van Plew Daniel P | ▼ Sell | Tax Withholding | 2,552 | $1.8M | 12/9/2025 |
| Andrew J. Murphy | ▼ Sell | Tax Withholding | 4,229 | $3.0M | 12/9/2025 |
| Marion McCourt | ▼ Sell | Tax Withholding | 1,021 | $716K | 12/9/2025 |
| George Yancopoulos | ▲ Buy | Option Exercise | 146,815 | $81.6M | 12/9/2025 |
| George Yancopoulos | ▼ Sell | Tax Withholding | 131,874 | $92.5M | 12/9/2025 |
| Jason Pitofsky | ▼ Sell | Tax Withholding | 989 | $705K | 12/8/2025 |
| Van Plew Daniel P | ▼ Sell | Tax Withholding | 1,906 | $1.4M | 12/8/2025 |
| Andrew J. Murphy | ▼ Sell | Tax Withholding | 1,699 | $1.2M | 12/8/2025 |
| Joseph J. Larosa | ▼ Sell | Tax Withholding | 1,396 | $995K | 12/8/2025 |
| Christopher R. Fenimore | ▼ Sell | Tax Withholding | 992 | $707K | 12/8/2025 |
| Marion McCourt | ▼ Sell | Tax Withholding | 1,336 | $952K | 12/8/2025 |
| Jason Pitofsky | ▲ Buy | Grant | 2,064 | $0 | 12/5/2025 |
| Van Plew Daniel P | ▲ Buy | Grant | 3,715 | $0 | 12/5/2025 |
| Andrew J. Murphy | ▲ Buy | Grant | 3,715 | $0 | 12/5/2025 |
| Marion McCourt | ▲ Buy | Grant | 2,476 | $0 | 12/5/2025 |
| Christopher R. Fenimore | ▲ Buy | Grant | 3,027 | $0 | 12/5/2025 |
| Joseph J. Larosa | ▲ Buy | Grant | 2,476 | $0 | 12/5/2025 |
| Joseph J. Larosa | ▲ Buy | Option Exercise | 14,450 | $8.0M | 11/20/2025 |
| Joseph J. Larosa | ▼ Sell | Tax Withholding | 12,686 | $9.3M | 11/20/2025 |
| Bonnie L. Bassler | ▲ Buy | Option Exercise | 760 | $282K | 11/20/2025 |
| Bonnie L. Bassler | ▼ Sell | Open Market | 760 | $570K | 11/20/2025 |
| Jason Pitofsky | ▼ Sell | Open Market | 431 | $281K | 11/7/2025 |
| Christine A. Poon | ▲ Buy | Option Exercise | 2,712 | $1.4M | 10/30/2025 |
| Andrew J. Murphy | ▼ Sell | Gift | 1,538 | $0 | 10/30/2025 |
| Christine A. Poon | ▼ Sell | Open Market | 650 | $424K | 10/29/2025 |
| Christine A. Poon | ▲ Buy | Option Exercise | 6,500 | $3.4M | 10/29/2025 |
| Christine A. Poon | ▼ Sell | Open Market | 2,735 | $1.8M | 10/29/2025 |
| Christine A. Poon | ▼ Sell | Open Market | 1,915 | $1.3M | 10/29/2025 |
| Christine A. Poon | ▼ Sell | Open Market | 100 | $66K | 10/29/2025 |
| Christine A. Poon | ▼ Sell | Open Market | 712 | $467K | 10/29/2025 |
| Christine A. Poon | ▼ Sell | Open Market | 388 | $255K | 10/29/2025 |
| Andrew J. Murphy | ▲ Buy | Option Exercise | 35,000 | $19.4M | 10/29/2025 |
| Andrew J. Murphy | ▼ Sell | Tax Withholding | 32,490 | $21.1M | 10/29/2025 |
| George L. Sing | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| David P. Schenkein | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Craig B. Thompson | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| N. Anthony Coles | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Huda Y. Zoghbi | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Arthur F. Ryan | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Christine A. Poon | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Kathryn Guarini | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Joseph L. Goldstein | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Michael S. Brown | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| Bonnie L. Bassler | ▲ Buy | Grant | 166 | $0 | 1/2/2025 |
| George L. Sing | ▼ Sell | Tax Withholding | 1,948 | $1.4M | 12/31/2024 |
| George L. Sing | ▲ Buy | Option Exercise | 3,338 | $1.4M | 12/31/2024 |
| Christine A. Poon | ▼ Sell | Other | 14 | $0 | 12/20/2024 |
| Van Plew Daniel P | ▼ Sell | Tax Withholding | 969 | $708K | 12/16/2024 |
| STAHL NEIL | ▼ Sell | Tax Withholding | 304 | $222K | 12/16/2024 |
| Andrew J. Murphy | ▼ Sell | Tax Withholding | 1,054 | $770K | 12/16/2024 |
| Marion McCourt | ▼ Sell | Tax Withholding | 759 | $555K | 12/16/2024 |
| Jason Pitofsky | ▼ Sell | Tax Withholding | 298 | $218K | 12/16/2024 |
| Joseph J. Larosa | ▼ Sell | Tax Withholding | 702 | $513K | 12/16/2024 |
| Christopher R. Fenimore | ▼ Sell | Tax Withholding | 491 | $359K | 12/16/2024 |
| Jason Pitofsky | ▼ Sell | Tax Withholding | 149 | $117K | 12/9/2024 |
| Christopher R. Fenimore | ▼ Sell | Tax Withholding | 1,140 | $897K | 12/9/2024 |
| STAHL NEIL | ▼ Sell | Tax Withholding | 466 | $367K | 12/9/2024 |
| Van Plew Daniel P | ▼ Sell | Tax Withholding | 492 | $387K | 12/9/2024 |
| Andrew J. Murphy | ▼ Sell | Tax Withholding | 492 | $387K | 12/9/2024 |
| Marion McCourt | ▼ Sell | Tax Withholding | 274 | $216K | 12/9/2024 |
| Joseph J. Larosa | ▼ Sell | Tax Withholding | 492 | $387K | 12/9/2024 |
| Jason Pitofsky | ▲ Buy | Grant | 907 | $0 | 12/6/2024 |
| Christopher R. Fenimore | ▲ Buy | Grant | 2,591 | $0 | 12/6/2024 |
| Van Plew Daniel P | ▲ Buy | Grant | 3,499 | $0 | 12/6/2024 |
| Andrew J. Murphy | ▲ Buy | Grant | 3,499 | $0 | 12/6/2024 |
| Marion McCourt | ▲ Buy | Grant | 2,332 | $0 | 12/6/2024 |
| Joseph J. Larosa | ▲ Buy | Grant | 2,332 | $0 | 12/6/2024 |
| Andrew J. Murphy | ▼ Sell | Gift | 1,185 | $0 | 11/8/2024 |
| Marion McCourt | ▲ Buy | Option Exercise | 1,000 | $381K | 11/1/2024 |
| Marion McCourt | ▼ Sell | Open Market | 1,000 | $845K | 11/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 4 | $4K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 2 | $2K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 3 | $3K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 3 | $3K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 4 | $4K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 3 | $3K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 1 | $1K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $5K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 9 | $9K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 7 | $7K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 9 | $9K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 12 | $13K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 12 | $13K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 9 | $9K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 6 | $6K | 10/1/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 9 | $9K | 10/1/2024 |
| Marion McCourt | ▲ Buy | Option Exercise | 1,000 | $381K | 10/1/2024 |
| Marion McCourt | ▼ Sell | Open Market | 1,000 | $1.1M | 10/1/2024 |
| George L. Sing | ▼ Sell | Gift | 1,200 | $0 | 9/4/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 8 | $9K | 9/3/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 5 | $6K | 9/3/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 4 | $5K | 9/3/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 4 | $5K | 9/3/2024 |
| Arthur F. Ryan | ▼ Sell | Open Market | 8 | $9K | 9/3/2024 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock
Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.
Regeneron Gets EU Approval for Libtayo Dosing, UBS Upgrades Stock. Regeneron received a positive recommendation from the EU's CHMP for an updated Libtayo dosing regimen across all approved cancer types. This regulatory progress follows strong earnings and new Phase III data for a treatment for FOP. UBS recently upgraded the stock to Buy and raised its price target to $978, citing the company's potential value.